What is Zacks Research’s Estimate for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Omnicell in a report issued on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.17 for the quarter, up from their prior estimate of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.18 EPS, FY2025 earnings at $0.86 EPS and Q1 2026 earnings at $0.27 EPS.

OMCL has been the subject of a number of other research reports. Barclays upped their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company dropped their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Benchmark reiterated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Omnicell has an average rating of “Hold” and a consensus target price of $50.00.

Omnicell Stock Performance

NASDAQ:OMCL opened at $45.31 on Thursday. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The firm’s 50-day simple moving average is $44.68 and its 200 day simple moving average is $42.64. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -116.18, a P/E/G ratio of 29.73 and a beta of 0.78.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp lifted its stake in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares during the period. GAMMA Investing LLC raised its holdings in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. KBC Group NV lifted its position in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares during the period. 1620 Investment Advisors Inc. boosted its stake in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Summit Global Investments bought a new position in Omnicell during the third quarter worth $221,000. Institutional investors own 97.70% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.